TRxADE Health (NASDAQ: MEDS), a pharmaceutical exchange platform provider, has filed for an extension to file its quarterly report. The company filed the extension on Form 10-Q for the second quarter pursuant to a Form 12b-25 filed with the U.S. Securities and Exchange Commission (“SEC”). According to the announcement, TRxADE is “not able to timely file its 10-Q by August 14, 2023, the original due date for such filing, without unreasonable effort or expense, because additional time is required to finalize its financial statements and related disclosures required to be included in the 10-Q in connection with the recent merger transaction it completed in July.” The company noted that it will release Q2 2023 financial results on Aug. 18, 2023, after the market closes.
To view the full press release, visit https://ibn.fm/QoVLg
About TRxADE Health Inc.
TRxADE is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the United States. The company operates the TRxADE drug-procurement marketplace serving more than 14,500 members nationwide, fostering price transparency and, under the Bonum Health brand, offering patient centric telehealth services. For more information about the company, please visit www.TRxADE.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
